



April 1, 2022
Announcement no. 4

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan or any jurisdiction in which such publication or distribution would be unlawful. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to purchase or subscribe for securities in United States, Canada, Australia or Japan or any other jurisdiction in which it would be unlawful to do so. Any failure to comply with this may constitute a violation of US, Canadian, Australian or Japanese securities laws or the securities laws of other states as the case may be. Any securities described herein may not be offered or sold in the United States absent registration or an exemption from registration; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the company that will contain detailed information about the company and management, as well as financial statements.

BioPorto A/S announces completion of rights issue; capital raised, total number of shares, and voting rights

BioPorto A/S (“BioPorto” or the “Company”) today announces the completion of the fully subscribed rights issue announced on 7 March 2022 (“the Offering”), raising gross proceeds of approximately DKK 100.4 million and estimated net proceeds of DKK 93.5 million. The 66,938,601 new shares will be admitted to trading and official listing on Nasdaq Copenhagen A/S under the Company’s permanent ISIN-code (DK0011048619), with the expected first day of trading being on Monday, 4 April 2022.

“The proceeds from this rights issue will enable our team to focus on BioPorto’s strategy to deliver the NGAL biomarker as the new standard of care in assessment of kidney health, prepare the company to commercialize and scale, and build a strong team dedicated to our mission,” said Tony Pare, BioPorto’s Chief Executive Officer.

BioPorto’s share capital has been increased by DKK 66,938,601 as a result of the completion of the Offering. Accordingly, the nominal value of the Company’s total share capital amounts to DKK 334,693,005 divided into 334.693.005 shares each carrying 1 voting right, corresponding to a total of 334,693,005 voting rights cf. section 32 of the Danish Capital Markets Act.

The Company’s articles of association have been updated to reflect the capital increase. The updated articles of association have been registered with the Danish Business Authority and are available at www.bioporto.com/governance.

For further information, please contact:

*Tim Eriksen, Investor Relations,
+45 61 68 77 79, email: investor@bioporto.com*

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers - tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.



BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. More information is available at www.bioporto.com.

Forward-looking statement disclaimer:

Certain statements in this announcement are forward-looking statements, which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts, including with respect to the timing, terms and consummation of the rights issue described herein and potential FDA clearance in pediatrics, development of the Company's U.S. organization and commercialization of The NGAL Test. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.